News & Events

Our Latest Updates and Publications

Filter by

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Orvida Pharma Announces Favorable Phase 1a Safety Data for KM-023, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome

Orvida Pharma Announces Favorable Phase 1a Safety Data for KM-023, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome

Orvida Publishes potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology

December 1, 2025

Orvida Publishes potential approach for Keratoderma therapy, in the Journal of Investigative Dermatology

Specific, High-Avidity Transient Receptor Potential Ion Channel Inhibitors Demonstrate...

Orvida has initiated its first-in-human Phase I trial of KM-023

Orvida has initiated its first-in-human Phase I trial of KM-023

Orvida has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety,

Orvida Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Orvida Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases

Financing co-led by BRM Group and existing investor Pontifax

Novel TRPV3 inhibitors demonstrate safety and efficacy in preclinical models

Novel TRPV3 inhibitors demonstrate safety and efficacy in preclinical models

In Phase Ib clinical study for the treatment of Palmoplantar Keratoderma...

Orvida Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology

Orvida Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology

and the International Pachyonychia Congenita Consortium Symposium

KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy

KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy

In Phase Ib clinical study for the treatment of Palmoplantar Keratoderma...

Orvida Pharma Appoints Dr. John Doux to its Board of Directors

Orvida Pharma Appoints Dr. John Doux to its Board of Directors

“We are pleased to welcome John to our board of directors at this exciting time for Kamari. John is a highly accomplished life science...

TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome

September 28, 2022

TRPV3 antagonist treatment reduces pro-inflammatory pathways in Olmsted syndrome

Olmsted Syndrome (OS) is a rare, very painful, and severe form of Palmoplantar Keratoderma...

Orvida Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

September 18, 2022

Orvida Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

Kamari, Founded by Pontifax and Arkin Bioholdings, is a clinical stage company developing proprietary drugs for complex dermatological...

No items found, Clear Filters.